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Harm reduction is an approach in drug policy based on health issues and human rights. 
The aim of this article is to present the essence of the harm reduction model, as well as 
its implementation in Mexico after the year 2006. The study is an attempt to answer the 
following research questions: firstly, what is the scale of psychoactive drugs consumption 
in Mexico – and what goes with it – its negative health implications; secondly, to what 
extent does the Mexican drug policy takes account of aspects related to public health? This 
analysis proves that Mexico lacks a comprehensive harm reduction strategy and the main 
role in implementing this model is played by civil society organizations.
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RESUMEN
La reducción de daños es un enfoque de la política de drogas basado en cuestiones de 
salud y derechos humanos. El objetivo de este artículo es presentar la idea principal 
del modelo de reducción de daños, así como su implementación en México a partir del 
año 2006. El estudio intenta responder a las siguientes preguntas de investigación: en 
primer lugar, cuál es la magnitud del consumo de drogas psicoactivas en México y sus 
implicaciones negativas para la salud; en segundo lugar, en qué medida la política 
de drogas de México tiene en cuenta los aspectos relacionados con la salud pública. 
Este análisis demuestra que México carece de una estrategia integral de reducción 
de daños y que el papel principal en la aplicación de este modelo lo desempeñan las 
organizaciones de la sociedad civil.
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Introduction
Psychoactive drugs1 represent a social construct meaning that in various time 
periods they were defined and valuated differently by sundry social groups. 
Over the years, influenced by the Age of Discovery and the development of 
science, they have been desacralized, i.e., drugs have been moved from the 
sacrum sphere, in which access to them was restricted and controlled by cer-
tain social groups, to the profanum realm, where drugs are used for the so-
called recreational purposes (Motyka & Marcinkowski, 2014). Greater drugs 
availability on the market, the emergence of new psychoactive substances 
and the lack of proper legal regulations pertaining to them caused health and 
social issues to mount. Most countries all over the world implemented the 
policy of drug prohibition as a response to these problems. Internationally, 
this policy is realised within international drug control regime. Nevertheless, 
global war on drugs has not yielded the expected results, it has not reduced 
demand and supply for psychoactive drugs. This fact is testified by the data 
from the report compiled in 2020 by the United Nations Office on Drugs and 
Crime which says that over the last twenty years there has been an increase in 
drugs consumption, as well as their number and types on the market. In 2018, 
269 million people took psychoactive drugs, which constitutes a 30% growth 
in comparison to 2009. Approximately 35.6 million people suffer from disor-
ders resulting from drug-taking and only 1 in 8 people in need receives me-
dical treatment, while among 11 million people taking psychoactive drugs by 
injection, 50% are reported to be suffering from type C hepatitis (HCV) and 
1.4 million are carriers of HIV (UN, 2020, p. 1). Therefore, experts point out 
that the presence of drugs in culture and social space is inevitable and, there-
fore, more measures and resources need to be committed to the elimination 
of negative health and social impacts connected with their consumption, such 
as: addictions, overdose, the spread of contagious diseases, or marginalisa-
tion and discrimination towards people taking drugs. Schemes aiming to curb 
such processes are realised within the so-called harm reduction2.  
The main objective of this article is to present the essence of harm reduc-
tion model and to outline its implementation in Mexico after the year 2006. In 
the global drug market, Mexico performs the functions of psychoactive drugs 
1  For the purposes of this article, expressions „drugs”, „psychoactive drugs”, “psychoactive 
substances” will be used interchangeably. These expressions denote illegal substances. 
2  Harm reduction may also concern alcohol abuse issues.
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producer3 and a transit country for drugs smuggling4, which is reflected in the 
organised crime groups activity, who profit by distributing and selling drugs 
(Nieto, 2018), thus generating violence which raises a serious issue for the 
country’s security. It needs to be noted that since 2006 Mexico’s drug policy 
has been mainly directed towards the militarisation in combating drug cartels 
(Jargiełło, 2018). Taking all the above issues into account, this article is an at-
tempt to answer the following questions: firstly, what is the scale of psychoac-
tive drug consumption and its negative health impacts?; secondly, to what ex-
tent does the Mexican drug policy allow for aspects related to public health? 
The following hypothesis has been put forward in this paper – Mexico lacks 
appropriate harm reduction strategy. To verify this claim, various methods 
and techniques of research have been used, for instance: institutional and legal 
analysis, analysis of literature and research, analysis of statistical data. 
The essence of harm reduction model 
Drug policy is one of the public policies pursued by a government or its re-
presentatives providing for a system of laws, regulations, courses of action, as 
well as budget priorities regarding psychoactive drugs. It encompasses a range 
of strategies involving issues such as: education, treatment, drug legislation, the 
police activities and control of borders5. Since the scope of drug policy is rather 
broad, three basic models may be distinguished. This article primarily centres 
around the harm reduction model, however, to fully understand its core, one 
must scratch beneath the surface and take a closer look at the other two. 
The most common approach is supply reduction with its underlying 
conviction that drugs are bad, and drug-taking affects health and societies 
in a negative way, thus the need to curb the amount of drugs on the market 
and hinder access to them, which can be achieved by inhibiting illegal pro-
duction of drugs and their distribution (Zamecka, 2018, pp. 112–115).  The 
production may also be constrained by crop eradication or by implementing 
the alternative development programmes. Moreover, this policy also entails 
the liquidation of illegal laboratories and controlling the chemical precursors. 
In addition, drug distribution is hindered by both police and border guards’ 
activities, for example – drug seizure (UN ODCCP, 2000, p. 69) Supply reduc-
tion involves legal control which makes use of harsh penalties or repressive 
measures. This essentially constitutes the policy of combating criminality by 
penal measures oriented on drug control and fighting drug crime. The model 
in question may take extreme forms such as: prohibition, capital punishment 
3  Heroine, marijuana, methamphetamine.
4  Cocaine.
5  Author’s own definition based on:  EMCDDA, 2017, p. 3; UN ODCCP, 2000, p. 23.
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which is often figuratively called war on drugs.
Demand reduction model constitutes a crucial component of drug poli-
cy in many countries. It refers to policies and schemes orientated on limi-
ting psychoactive drugs consumption. Contrary to the former model, one of 
the assumptions of demand reduction model is the fact that the existence of 
a drug-free society is an unreal concept. Yet, the risk of reaching out for drugs 
needs to be reduced by taking preventative and therapeutic measures6. This 
model involves strategies regarding prevention and education i.e., raising so-
cial awareness and compounding knowledge of threats related to drug con-
sumption, especially among adolescents. The key factor seems to be enabling 
easy access to high quality services falling within therapy and treatment of 
people addicted to psychoactive drugs, however the mandatory requirement 
to receive such help is to stop using drugs and stay sober (Zamecka, 2018, pp. 
115–117). 
The model which addresses the drug issue in the most humanitarian and 
health-promoting way is harm reduction. According to the definition provi-
ded by a non-governmental organization Harm Reduction International: 
Harm reduction refers to policies, programmes and practises that aim to 
minimise negative health, social and legal impacts associated with drug use, 
drug policies and drug laws. Harm reduction is grounded in justice and hu-
man rights. It focuses on positive change and on working with people without 
judgement, coercion, discrimination (…). (Harm Reduction International, 
2021)
It does not stigmatise drug users, claiming that drug consumption and 
addiction stems from various factors: social, environmental, cultural, and per-
sonal. As in the case of demand reduction, drug-addicted people should be 
treated as people suffering from an illness who ought to be offered treatment. 
Contrary to the previous model, it is not mandatory for a person to stop using 
psychoactive substances and keep drug-abstinence. At the bottom of this mo-
del lies the concern for the well-being of a person who takes and is addicted 
to psychoactive drugs and the concern for public health which manifests itself 
in hindering the “harm” resulting from taking drugs such as, for example, the 
spread of HIV across the population or other diseases or viruses, which may 
be the result of some “risky behaviour” – for instance – taking drugs by injec-
tion, using non-sterile injection equipment which had been used before.
6  This model mainly involves using the social policy measures. It must be borne in mind 
that the demand might also be curbed using criminal law. The so-called “deterrence mechanism” 
is supposed to prevent people from drug consumption in the fear for penal responsibility (Kra-
jewski, 2001, pp. 69–70).
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Harm reduction entails a comprehensive set of services recommended by 
the World Health Organization (WHO), United Nations Office on Drugs and 
Crime (UNODC) and the Joint United Nations Programme on HIV and AIDS 
(UNAIDS) (UNAIDS, 2019, p. 17).
These activities include:
1.	 Needle and syringes exchange programmes7.
2.	 Drug dependence treatment, including opioid substitution therapy8.
3.	 Testing for HIV services.
4.	 Anti-retrovirus therapy9.
5.	 Prevention and treatment of sexually transmissible diseases.
6.	 Condom distribution programmes for people injecting drugs and their se-
xual partners.
7.	 Directed information, education, and communication.
8.	 Prevention, vaccination, diagnostics and treatment of type B and C 
hepatitis.
9.	 Prophylaxis, diagnostics, and treatment of tuberculosis.
10.	Distribution of naloxone10.
Apart from the above-mentioned components, harm reduction might also 
involve such aspects as: the existence of the so-called consumption rooms, in 
which drugs may be taken under the supervision of qualified staff and in hy-
gienic conditions; giving out dressings and disinfection materials; housing ini-
tiatives for the addicted homeless; psychosocial support and providing infor-
mation about drugs and their safe use (Harm Reduction International, 2021).
Despite the obvious differences between the above-mentioned models, 
they should be treated complementarily, which means that they can co-exist 
and complement one another. In effect, however, most countries base their 
drug policy on supply reduction, which is expensive, and often does not yield 
the desired results. Therefore, research-based attitude change towards drug is-
sue is necessary. According to UNAIDS report from 2019, implementing com-
7  The exchange involves giving out sterile materials to people taking drugs by injection with 
the intention to lower the risk of them getting infected with HIV and HCV and to collect used 
equipment from them which is intended to prevent random people from being exposed to it 
(Michalewski, 2021, p. 26).
8  It involves giving people addicted to heroin and other opiates its synthetic equivalent – 
mainly methadone. This action aims to combat withdrawal syndrome and to prevent the rejec-
tion effect thanks to which a patient will be able to function in a society. Methadone therapy 
leads to a decrease in or a complete withdrawal from drug-taking (Michalewski, 2021, p. 26).
9  It involves treating people infected with HIV aiming to improve their health condition, 
restore their immune system, lower the risk of AIDS progression and the risk of other people 
getting infected.
10  Distribution of naloxone is recommended by WHO. Naloxone is a substance which 
blocks opiates. If given at the right moment to a person who overdosed drugs, it will prevent 
death and save the person’s life. Typically, other addicted people are witnesses to overdose, that is 
why, it is recommended that they have naloxone so that they could react in time (Michalewski, 
2021, p. 27).
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fections, problem drug use, overdose deaths and other harms. Countries that 
have successfully scaled up harm reduction have experienced steep declines in 
HIV infections among people who inject drugs” (UNAIDS, 2019, p. 2). Harm 
reduction arouses some controversy, but it appears to be of the most humani-
tarian, pragmatic and health-promoting nature. Its main goal is to improve the 
quality of life of people taking drugs without imposing abstinence upon them. 
This, though, should not be associated with promoting the use of psychoactive 
substances, but rather the care for an individual and the whole society. 
Drug use in Mexico and its negative health implications
The key study on the tendencies of psychoactive drugs use is National Trends 
in Alcohol, Tobacco and Drugs Consumption in 2016–2017 (Encuesta Nacio-
nal de Consumo de Drogas, Alcohol y Tabaco, ENCODAT 2016–2017), which 
was conducted in 2016 when 56,877 people were interviewed, 12,440 of whom 
were adolescents aged 12–17 and the other 44,437 were adults aged 18–65. 
According to this research, there has been an increase in consumption of “any 
drug”11 taken by a person at a certain stage of their lives. In 2011, 7.8% of inter-
viewees admitted to having used such drugs, while in 2016 the number rose to 
10.3%. Between 2011–2016 the consumption of illegal drugs used at a certain 
stage of a person’s life rose from 7.2% to 9.9% with cannabis being the most 
popular drug (used by 8.6% of people surveyed) followed by cocaine with 
3.5% of people admitting to its consumption. Moreover, 0.6% of people who 
took part in this study exhibited a possible consumption dependency on drug 
use in the last year and 20.3% of them signed on for treatment. Interestingly, 
in recent years the average age of people who start using drugs decreased from 
20.6 in 2002, 18.7 in 2008, 18.8 in 2011 to 17.8 in 2016 (Encuesta Nacional…, 
2017; CONADIC, 2017, pp. 50, 56, 115).
In Mexico, a staggering 164,157 people take drugs by injection, and bea-
ring in mind the whole population of the country, it is the highest number 
in Latin America. For comparison, in Argentina the number of people who 
inject drugs amounts to 8,144, in Colombia to 14,893. Harm Reduction In-
ternational report from 2020 provides a percentage number of HIV, type C 
(anti-HCV) and type B (anti-HBsAg) carriers among people who inject drugs. 
The prevalence rate of HIV looks the following: in Mexico 4.4% of people, 
in Argentina 3.5% and in Colombia 5.5%. Nevertheless, the most worrying 
11  The expression “any drug” refers to the use of medical substances (opioids, sedatives, 
barbiturates, or amphetamine) without prescription or their consumption exceeding a doctor’s 
recommendation over a longer period of time or the use of illegal drugs such as: marijuana, 
cocaine, cocaine paste, crack, hallucinogens, intoxicative inhalants, heroine, and stimulants of 
methamphetamine type and other substances such as ketamine or GHB etc. 
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data concern the prevalence of type C hepatitis. In Mexico, 96% people who 
use injected drugs are carriers of this disease, which constitutes the highest 
number in the region, and one of the highest in the world. As a comparison, 
in Argentina this rate comes to 4.8% and in Columbia it totals 31.6%, whereas 
in the case of hepatitis B, this rate only amounts to 0.2% in Mexico, 1.6% in 
Argentina and there are no data available for Colombia (Harm Reduction In-
ternational, 2020, p. 100).
Territorial data show that it is in the northern areas of the country that 
the issue of drug consumption and addictions is most apparent. This fact is 
reflected in the research conducted in 2017–2018 by the National Institute of 
Psychiatry Ramón de la Fuente Muñiz (Instituto Nacional de Psiquiatría Ra-
món de la Fuente Muñiz, INPRM) in association with the Ministry of Health 
and with the participation of three non-governmental organisations12. This 
study concerns the use of heroin in three major, cross-border cities in Mexico, 
namely: Tijuana (Lower California), San Luis Rio Colorado (Sonora) and Ciu-
dad Juarez (Chihuahua), and it was conducted in addiction treatment centres 
on a group of 600 people and at consumption sites on a group of 391 people. 
Based on the results, it has been concluded that in the population of people 
taking heroin, the majority were male, migrants who tried to cross the border 
and/or were deported from the USA. These individuals also had had experi-
mentation phases with other psychoactive drugs – as many as 96.5% had used 
marijuana at least once in their lifetime, and 91.3% used cocaine. In addition, 
the research indicates that 66.8% of surveyed people experienced overdose at 
some point in their lives, which represents a total of 401 cases. The data regar-
ding risky practices connected with taking drugs also need to be taken into 
consideration. As many as 75.1% of interviewees admitted having lent a used 
syringe to other people, while 69.8% admitted having used a syringe which 
had been used before. Thereupon, a high rate of reactive hepatitis C cases has 
been reported in treatment centres. It amounts to 76.9%, which represents 455 
cases. In the context of negative social implications such as discrimination or 
marginalisation, as many as 58.6% of the population surveyed claimed to have 
been treated with contempt and to have been rejected or offended by a family 
member, while 49.5% have been rejected by potential employers during the 
job-seeking process (Fleiz-Bautista & Domínguez-García …, 2019, pp. 61, 68, 
90, 93, 162). 
The problem of drug consumption and the number of addictions surge in 
northern states stems from the specific character of these areas, namely, the 
fact that they border the southern states of the USA. These are territories of 
both geographical and goods and services mobility, where people cross the 
border both for touristic and earning purposes. Moreover, these are key points 
of smuggling drugs into the USA. For these reasons, in some parts of the ci-
ties drug trafficking and consumption, prostitution and crime have simmered. 
12  Prevencasa, Integración Social Verter and Programa Compañeros.
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seal the border, resulted in people – who did not manage to cross the border 
or have been deported from the USA – having to settle in cross-border cities. 
Consequently, no prospects and source of income made them resort to psy-
choactive drugs. It must be stated that due to the opioid crisis13 in the USA, in 
northern Mexican states an increase in heroin and fentanyl consumption, re-
sulting from the change in drug demand, and thus, the heroin price reduction, 
has been noted. Additionally, as a result of security police operations, a share 
of drugs produced in Mexico does not make it across the border and reach 
its American consumers. Therefore, to make up for the financial loss, drug 
cartels try to stimulate and meet the local drug demand (Bonello, November 
1, 2019), which results in the increase in psychoactive drug consumption in 
the country.  
The implementation of harm reduction model in Mexico
In the context of public health, Mexican drug policy is regulated by several 
legal acts. The fourth article of the Political Constitution of the United States 
of Mexico (Constitución Política de los Estados Unidos Mexicanos) states that 
every person has the right to health (Diario Oficial de la Federación, May 28, 
2021). The control and supervision over particular psychoactive drugs have 
been defined in the General Health Law (Ley General de Salud), which pro-
vides a definition of the so-called “therapeutic values” of psychotropic subs-
tances14, and determines whether they pose a threat to public health (Diario 
Oficial de la Federación, August 20, 2009). Another important piece of legis-
lation concerning drugs which took effect on 21st of August 2009 is the decree 
known as Small-Scale Drug Law (Ley de narcomenudeo) which decriminalises 
psychoactive drugs and determines the maximum number of dosages allowed 
for personal and direct use without facing criminal charges15. Any individual 
taking more drugs than stated in statutory law, caught by the police for the 
third time, will have to attend compulsory rehab treatment. Moreover, the law 
determines the kinds of crime committed against health in the context of drug 
dealing, and more importantly, designates the following terms: “user”, “addic-
ted person” and “retailer” (Hernández, 2010).
13  By the term “opioid crisis” we refer to the epidemic of prescribed opioid medication ad-
diction (mainly fentanyl) which goes back to 1990s. Since 2017 a steep increase in opioid addic-
tions and overdose deaths has been observed. See: National Institute…, March 11, 2021.
14  The term “psychotropic substances” refers to substances affecting central nervous system. 
It is synonymous to “psychoactive drugs” frequently used in legal parlance.
15  The 2009 reform eliminates legal sanctions for the possession of the following drugs: 0.5 
g of cocaine, 50 mg of heroin, 0.015 mg of LSD, 40 mg of methamphetamine, 5 g of marijuana 
(Mackey & Werb…, 2014).
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The most important legal instrument regulating issues regarding drug 
use in terms of health is the Official Mexican Standard 028 (Norma Oficial 
Mexicana, NOM-028-SSA2-2009) which pertains to the prevention, treat-
ment, and control of addictions. The standard provides a definition of harm 
reduction which, in a nutshell, says that it is a complex of activities aiming 
to avoid completely or limit the risk and curb harms caused by psychoactive 
drugs consumption. Thus, it is imperative to provide treatment and prophy-
laxis. This does not necessarily mean abstinence. In the case of HIV/AIDS, it 
is a strategy which involves providing information about HIV/AIDS to drug 
users; instructing them how to properly clean syringes and how to use sterile 
needles and syringes; distributing condoms, chlorine, gauze bandages, as well 
as giving medical advice, conducting HIV tests; community service for people 
who inject drugs, creating interdisciplinary advice groups regarding drug con-
sumption. Such activities are the safest and most effective method of limiting 
the HIV transmission among individuals who inject drugs (CNDH, 2009). 
This definition corresponds to the UN-promoted definitions, nongovernmen-
tal organisations, and academic centres. 
There are two methods of treating people addicted to psychoactive sub-
stances available in Mexico, namely: ambulatory and stationary. The former is 
represented by 341 governmental Primary Health Care Centres for Addictions 
(Centros de Atención Primaria en Adicciones, CAPA), 104 external consulting 
units of the Centres for Youth Integration (Centros de Integración Juvenil) and 
medical services provided by an unspecified number of private clinics. As far 
as the stationary care goes, it consists of 11 hospital wards of the Centres for 
Youth Integration, the so-called public housing units (45) and 2,108 private 
care facilities for the addicted, many of which were set up over a dozen years 
ago. All this constitutes the civil society’s response to the fact that such fa-
cilities are extremely scarce in the country. Almost half of these facilities are 
registered, and 348 entities are officially approved, which means that medical 
services provided there comply with the rules of law (CONADIC, 2019, p. 44). 
Within the framework of harm reduction, needle exchange schemes 
(NSP) are realised. However, according to the data obtained from the Harm 
Reduction International report from 2020, less than 5% of people inject-
ing drugs have access to such programmes. Heroin addicts may use opi-
oid agonist therapy (OAT), which primarily involves methadone therapy. 
Nonetheless, neither NSP nor OAT are accessible for the inmates. In Mexico, 
naloxone is distributed with the intention to prevent deaths resulting from 
opioids16 overdose. People who take drugs do not have the possibility to use 
the so-called drug consumption rooms (DCR), with only the city of Mexicali 
having this type of facility available. Yet, this place is not officially supervised 
16  Opioids are a group of substances including opiates (among others opium, morphine, and 
heroin) and synthetic opioids (for instance fentanyl) and pharmaceutical opioids (prescribed 
medicine). 
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2020, p. 100).
Detailed data showing precise information regarding the realisation and 
financing of harm reduction schemes are missing. It is known that in the 
last 10 years public health expenditure fluctuated between 2.5% and 2.9% 
of the country’s Gross Domestic Product (Méndez, 2020). It needs to be 
stressed that during the presidential term of Felipe Calderón (2006–2012), 
who declared a “war on drug cartels”, as much as 97.07% (790 billion pe-
sos) of overall drug policy expenditure was channelled to law enforcement 
activities, and as little as 2.91% (23 billion pesos) was used for prophylaxis 
and treatment including human rights programmes (Zedillo Ponce de León, 
Pérez Correa González…, 2019, p. 42). The public institution coordinating 
and financing harm reduction is the National Centre for the Prevention and 
Control of HIV and AIDS (Centro Nacional para la Prevención y el Control 
del VIH y el Sida, CENSIDA). It subsidises projects realised by private sec-
tor – only to a small extent, though. Between 2011–2017 CENSIDA financed 
31 social and research programmes, 19 of which were realised in conjunction 
with nongovernmental organisations. A 23 million pesos investment went 
directly to 44,444 and indirectly to 22,468 participants (Magis-Rodríguez 
& García-Sánchez…, 2018, p. 155). Nongovernmental organisation Global 
Fund was an important entity financing harm reduction operations. From 
January 2011 until December 2013, it aided the HIV struggle in Mexico ap-
propriating 34,680,258 US dollars (Global Fund, 2021) for the cause. How-
ever, due to the country’s increasing GDP, financial support was terminated, 
which translated to the limitation of harm reduction services by decreasing 
the number of civil society organisations which, at the time, did not receive 
enough funding from the Mexican government. 
Essentially, it is the civil society organisations that play a major role in 
implementing harm reduction. This funding has been in effect since 1988 with 
the support of international organisations and academic centres (Ospina-Es-
cobar, September 23, 2019). Thanks to their interventions, people with a drug 
abuse problem living in extreme poverty on the fringes of society may gain 
access to health services. These organisations centre around Mexican Harm 
Reduction Network (Red Mexicana de Reducción de Daños, REDUMEX), 
whose members include people taking drugs, former drug users, activists, and 
scientists. According to the CENSIDA data, in 2014 there existed 38 regis-
tered organisations in the north of the country. However, by 2017 this num-
ber had dropped to 8. The number of facilities offering replacement therapy 
also decreased significantly. In 2013, CENSIDA recorded 21 such facilities na-
tionwide, but in 2017 there were just 10. These facilities were shut down also 
because of the medication deficit. The depletion of financial backing also re-
sulted in the reduction of syringes distribution to people who inject drugs. The 
biggest number of syringes was given out during the realisation of the Global 
Fund programme in 2013 when the number of syringes per person amounted 
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to 19.7 while in 2017 it dropped by 30% and came to 6.2 syringes per person 
annually (Ospina-Escobar, June 11, 2019). Considering WHO recommenda-
tions, these numbers were low17. 
Although civil society organisations are the key entity providing harm re-
duction services, in 2019, President Andrés Manuel López Obrador announced 
that they would not be subsidised by the state. This decision was legitimised by 
the government’s fight against corruption, financial abuse, and fraud. Accord-
ing to Angélica Ospina Escobar from REDUMEX, the lack of governmental 
support is going to hit smaller organisations, which do not have international 
backing and are more of a communal nature, the hardest, meaning that fre-
quently they are the only service provider in terms of harm reduction among 
local communities (Ospina-Escobar, June 11, 2019). It must be borne in mind 
that the lack of funds is going to hinder the process of helping people in need. 
Consequently, it may increase the chances of HIV epidemic occurring in the 
future. The data regarding the efficiency of harm reduction schemes in terms 
of reducing the number of infections were published in 2019 in Salud Mental 
scientific journal. It has been calculated that in Mexico, between 2015–2018, 
among 66,973 people who inject drugs, 869 HIV infections were successfully 
prevented. The total CENSIDA’s investment spent on harm reduction came to 
13,206,323.20 pesos, which meant that the average cost of preventing 1 HIV 
infection amounted to 15,197 pesos, whereas an annual anti-retrovirus treat-
ment of an infected person came to 31,344 pesos (Valenzuela-Lara, Ponce-
Ramos et al., 2019, pp. 160–161). It may be concluded that prevention is more 
cost-effective than treatment since the cost of preventing a single infection is 
50% lower than an annual treatment cost of an infected person whose survival 
rate may reach 20 years. 
Presidential decree concerning funding restrictions for civil society or-
ganisations proves that the government continues their predecessors’ drug 
policy which, above all, relies on supply reduction, with little regard giv-
en to the issue of public health. Even though The National Development 
Programme for years 2019–2024 (Plan Nacional de Desarrollo 2019–2024) 
(Diario Oficial de la Federación, July 12, 2019) highlighted the necessity to 
reformulate drug policy, put an end to drug war and adopt the prevention 
strategy treatment of addictions, in effect, the government did not devise 
any strategy in this respect. Mexico lacks the proper system which would be 
able to monitor the efficacy of such programmes, and the one which would 
include data coming both from state institutions and private entities, which 
in turn, would make it possible to coordinate activities in a better way and 
to provide more effective health care for patients, thus curbing drug-related 
social and health harms.   
17  WHO recommends distributing 200 syringes per person annually.
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Mexico is among the states most severely affected by the negative impacts of 
drug prohibition related to combating organised crime groups. What is more, 
in recent years the use and abuse of psychoactive drugs has posed a serious 
health and social issue in the country – the fact which is related to the increase 
in HIV and HCV infections, as well as the marginalisation and discrimination 
of drug addicts. It can be noticed that drug problem affects different parts of 
the country to a varying degree, which is mainly caused by an array of socio-
economic factors and the proximity of the USA. 
Mexico lacks an integrated approach to drug policy which would rely on 
harm reduction to a greater extent and whose purpose would be to contain 
the negative health, social and economic implications of taking drugs. Des-
pite the existing legal mechanisms regulating this model, in effect, they do 
not translate into any particular strategy. There is no public institution being 
solely responsible for the coordination of harm reduction programmes. These 
activities rest with CENSIDA, whose goal is to prevent the spread of HIV and 
AIDS or HCV across society. However, it must be borne in mind that harm 
reduction should also encompass other aspects aiming to improve the general 
well-being and quality of life of people taking psychoactive drugs. In Mexico, 
it primarily concerns the needle and syringe exchange scheme and substitutio-
nal programmes. These activities are essentially performed by the civil society 
organisations, which are not sufficiently subsidised by the government. 
In recent years, in Mexico there has been the liberalisation of drug law18. 
Still, there are no projects aiming to protect public health which would ob-
serve human rights, while experts emphasise the fact that positive effects of 
decriminalisation or legalisation of psychoactive substances depend on the 
degree to which the harm reduction model or preventative schemes have been 
implemented. Ensuring the appropriate harm reduction services for people 
taking drugs is crucial, especially now, during COVID-19 pandemic, when ac-
cess to health is restricted – the consequences of which most deeply affect the 
addicted living in extreme poverty. It needs to be stressed that by signing The 
Sustainable Development Goals, Mexico declared that AIDS epidemic should 
be contained by 2030. In 2020, the Ministry of Health announced the launch 
of the national programme whose purpose is to eliminate type C hepatitis, 
viewed as a public health issue, by 2030. Nevertheless, the above-mentioned 
goals will not be realised without implementing a proper harm reduction stra-
18  Since 2017, medical use of marijuana has been legal in Mexico. In 2018, the Supreme 
Court pronounced that the ban on possessing and cultivating marijuana is non-constitutional 
and it ordered that the appropriate law be changed in that respect. According to the stand ready 
legislative bill, adults will be allowed to possess up to 28 grams of marijuana for personal use and 
cultivate up to 6 plants. The bill is meant to regulate issues concerning the rules of the operation 
of commercial market and the system of granting licenses (Lopez, July 14, 2021). 
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tegy which should allow for the diversity of the society including aspects, such 
as: sex, LGBT+ or the indigenous people. 
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